Gate Bioscience closed a $65 million financing to move its proprietary “molecular gate” class of small‑molecule protein degraders toward first‑in‑human studies. The company is developing degraders intended for immune and CNS targets and says its chemistry offers an unconventional route to remove disease‑causing proteins. The new capital will support IND‑enabling work and early clinical development; investors and partners were not named in the summary. Gate’s approach represents a divergent tactic within the broader targeted‑protein‑degradation field — focusing on small‑molecule modalities that may have different tissue distribution and safety profiles compared with PROTACs — and the funding underscores continued investor appetite for novel degrader chemistries.